Biomarkers in spondyloarthropathies

10Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The study of biomarkers in spondyloarthroparhy (SpA) has emerged to be a very important field of research. This is particularly because the two commonly used biomarkers, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), are of very low sensitivity and specificity. The second reason is, with advances in the treatment of SpA by the very expensive tumor necrosis factor-α (TNF-α) blockers, for cost-effectiveness, clinicians need to be much more accurate in predicting disease progression, evaluating disease activity and monitoring therapeutic efficacy. This review focuses on several biomarkers of promise: matrix metalloproteinases 3 (MMP-3), Type II collagen neoepitope (C2C and C1-2C), C-propeptide of Type II collagen (CPII), aggrecan 846 epitope, macrophage colony stimulating factor (M-CSF), serum amyloid A (SAA) and Interleukin-6 (IL-6). The results summarized in Table 1 call for a co-ordinated effort for systematic studies of existing biomarkers and for search for new candidates. © 2009 Landes Bioscience and Springer Science+Business Media.

Cite

CITATION STYLE

APA

Chen, C. H., Yu, D. T. Y., & Chou, C. T. (2009). Biomarkers in spondyloarthropathies. Advances in Experimental Medicine and Biology, 649, 122–132. https://doi.org/10.1007/978-1-4419-0298-6_9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free